| Title | Mesonephric Adenocarcinoma in a Young Male Patient. |
| Publication Type | Journal Article |
| Year of Publication | 2025 |
| Authors | Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A, Fomchenkova V, Yunusova L, Smirnova S, Elemento O, Nauseef J, Sternberg CN |
| Journal | Anticancer Res |
| Volume | 45 |
| Issue | 2 |
| Pagination | 619-623 |
| Date Published | 2025 Feb |
| ISSN | 1791-7530 |
| Keywords | Adenocarcinoma, Adult, Class I Phosphatidylinositol 3-Kinases, Humans, Male, Mutation, Tuberous Sclerosis Complex 2 Protein |
| Abstract | BACKGROUND/AIM: Mesonephric adenocarcinoma in males is an exceptionally rare malignancy arising from mesonephric remnants. Accurate diagnosis requires thorough histopathological and molecular analysis. CASE REPORT: A 33-year-old male presented with right lower quadrant pain, and imaging revealed a pelvic mass compressing adjacent structures. Biopsy confirmed mesonephric adenocarcinoma. Genetic profiling revealed mutations in tuberous sclerosis complex 2 (TSC2) and phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha (PIK3CA), offering potential for targeted therapy. CONCLUSION: This case highlights the diagnostic and therapeutic challenges of mesonephric adenocarcinoma in males. Molecular profiling provided insights into tumor biology and potential targeted treatments. Multidisciplinary collaboration and surveillance remain essential for managing rare malignancies effectively. |
| DOI | 10.21873/anticanres.17449 |
| Alternate Journal | Anticancer Res |
| PubMed ID | 39890190 |